Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02QWK
|
|||
| Drug Name |
SHP647
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 3 | [1] | |
| Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [2] | ||
| Company |
inhibitor, Lexington, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucosal addressin cell adhesion molecule 1 (MADCAM1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Intestinal immune network for IgA production | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Pathway Interaction Database | a4b7 Integrin signaling | |||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03259334) Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 301). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.